Core Laboratories (CLB) Long-Term Deferred Tax (2022 - 2026)

Core Laboratories' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $71.3 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 5.55% year-over-year to $71.3 million in Q1 2026; TTM through Mar 2026 was $71.3 million, a 5.55% increase from a year earlier, with the FY2025 full-year figure at $67.4 million, down 3.21% from the prior year.
• Long-Term Deferred Tax improved to $71.3 million in Q1 2026 per CLB's latest filing, from $67.4 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $72.3 million in Q3 2023 and bottomed at $66.3 million in Q1 2024.
• The 5-year median for Long-Term Deferred Tax is $69.6 million (2024), against an average of $69.4 million.
• Across the five-year window, Long-Term Deferred Tax dropped 3.29% in 2024 and rose 5.55% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $68.6 million in 2022, then advanced by 0.92% to $69.2 million in 2023, then rose by 0.6% to $69.6 million in 2024, then fell by 3.21% to $67.4 million in 2025, then grew by 5.81% to $71.3 million in 2026.
• Per Business Quant, the three latest CLB Long-Term Deferred Tax figures stand at $71.3 million (Q1 2026), $67.4 million (Q4 2025), and $70.5 million (Q3 2025).